press release

May 5, 2017

Alnylam, Medtronic, and CHDI Foundation Form Collaboration to Advance RNAi Therapeutics for the Treatment of Huntington’s DiseaseCAMBRIDGE, Mass. & MINNEAPOLIS & NEW YORK (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Medtronic Inc. (NYSE:MDT), and CHDI Foundation, Inc., announced today that they have formed a collaboration to advance ALN HTT, a novel drug device combination for the treatment of ...

press release

May 5, 2017

Alnylam Comments on Recent Roche Restructuring and Implications for RNAi TherapeuticsCAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, commented today on Roche’s corporate restructuring and its implications on RNAi therapeutics. Specifically, Roche announced today their decision to effect a broad based corporate restructuring that will result in discontinuation of certain activities ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Third Quarter 2010 Financial Results – Continues to Advance Pre Clinical and Clinical Pipeline of RNAi Therapeutics – – Finalizes Corporate Restructuring Related to Completion of Novartis Alliance – – Maintains Strong Balance Sheet with $372 Million in Cash – CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, ...

press release

May 5, 2017

- Genzyme to Obtain Significant Global Rights to Alnylam's Pipeline Alnylam Retains Most Product Rights in North America and Western Europe Genzyme Becomes Major Alnylam Shareholder through $700 Million Equity Investment PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced today that ...

press release

May 5, 2017

- New Collaboration Expected to Accelerate and Expand Global Product Value for RNAi Therapeutic Genetic Medicine Pipeline, Including "Alnylam 5x15" Programs Alnylam Retains Broad Product Rights in North America and Western Europe and Genzyme Obtains Rights to Access Alnylam's Genetic Medicines Pipeline in the Rest of World and Receives Co Development, Co Commercialization Rights or Global ...

press release

May 5, 2017

- Announced Major Business Transactions Including Transformational Alliance with Genzyme for RNAi Therapeutics as Genetic Medicines and Acquisition of Merck RNAi Assets and Sirna Therapeutics Subsidiary Initiated APOLLO Phase 3 Study with Patisiran (ALN TTR02) for the Treatment of Transthyretin (TTR) Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP) Initiated Phase 2 Study with ALN ...

press release

May 5, 2017

- Strategic Transaction Positions RNAi Assets for Future Advancement through Alnylam's Commitment to RNAi Therapeutics CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. ("Sirna Therapeutics"), comprising intellectual property and RNAi assets including pre clinical therapeutic candidates, chemistry, ...

press release

May 5, 2017

— Reported Positive Clinical Data with ALN TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Mediated Amyloidosis (ATTR), Demonstrating Human Translation of GalNAc siRNA Conjugate Delivery Platform — — Advanced Patisiran (ALN TTR02), an RNAi Therapeutic Targeting TTR for the Treatment of ATTR, Toward Phase III Trial — — Filed Clinical ...

press release

May 5, 2017

— Reported Positive Clinical Data from Two "Alnylam 5x15" Programs: ALN TTR02 for the Treatment of Transthyretin (TTR) Mediated Amyloidosis (ATTR) Patients with Familial Amyloidotic Polyneuropathy (FAP) and ALN TTRsc for the Treatment of ATTR Patients with Familial Amyloidotic Cardiomyopathy (FAC) — — Advanced Additional "Alnylam 5x15" Programs with Key Data Presented at Scientific Meetings — ...

press release

May 5, 2017

— ALN TTRsc Achieves Greater than 80% Knockdown of Serum TTR and is Found to be Generally Safe and Well Tolerated — — Results Establish Human Translation of Alnylam's Proprietary GalNAc siRNA Conjugate Platform for Subcutaneous Administration of RNAi Therapeutics with Wide Therapeutic Index — — Data to be Presented at the Annual Scientific Meeting of the Heart ...